Interestingly, the association of KMT2C mutations with rapid progression and drug resistance in AR-directed treatment was only found in the HSPC stage, which prompts the use of liquid biopsy for early detection of KMT2C mutations in prostate cancer in order to provide in-time treatment outcome prediction. The gene discussed is AR; the disease is prostate cancer.